Business Update

LG Life Sciences receives European marketing authorization for human growth hormone

Published in Drug Week, June 16th, 2006

LG Life Sciences reported that its strategic development partner in Europe, Biopartners GmbH, has obtained European marketing authorization for globally developed biological product recombinant human growth hormone Valtropin; daily formulation.

Valtropin, which is similar to domestic trademarked Eutropin, is a recombinant product originally developed in Korea by LG Life Sciences in 1993 for treatment of GHD Children. Since its successful launch in Korea, it continues to rank as the top market share holder in the Korean domestic market, competing against multinational products.

Since 1998, LG Life Sciences has been upgrading its manufacturing facility...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-06-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry